BSE Live
Mar 27, 16:01Prev. Close
1347.45
Open Price
1324.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:59Prev. Close
1346.60
Open Price
1342.00
Bid Price (Qty.)
1325.40 (17)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Dr Lal PathLabs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 59.70 | 46.25 | 35.28 | 41.61 | 33.93 | |
| Diluted EPS (Rs.) | 59.61 | 46.18 | 35.17 | 41.48 | 33.85 | |
| Cash EPS (Rs.) | 75.54 | 55.21 | 44.92 | 50.32 | 41.98 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 255.32 | 227.56 | 202.70 | 177.15 | 146.03 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 255.32 | 227.56 | 202.70 | 177.15 | 146.03 | |
| Dividend / Share(Rs.) | 24.00 | 24.00 | 12.00 | 12.00 | 20.00 | |
| Revenue from Operations/Share (Rs.) | 281.32 | 235.60 | 212.20 | 224.69 | 178.84 | |
| PBDIT/Share (Rs.) | 92.94 | 74.19 | 60.85 | 67.58 | 55.03 | |
| PBIT/Share (Rs.) | 76.89 | 65.02 | 51.00 | 58.54 | 46.66 | |
| PBT/Share (Rs.) | 74.32 | 61.81 | 46.88 | 55.12 | 44.88 | |
| Net Profit/Share (Rs.) | 59.49 | 46.04 | 35.07 | 41.28 | 33.61 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 33.03 | 31.49 | 28.67 | 30.07 | 30.77 | |
| PBIT Margin (%) | 27.33 | 27.59 | 24.03 | 26.05 | 26.08 | |
| PBT Margin (%) | 26.41 | 26.23 | 22.09 | 24.53 | 25.09 | |
| Net Profit Margin (%) | 21.14 | 19.54 | 16.52 | 18.37 | 18.79 | |
| Return on Networth / Equity (%) | 23.29 | 20.23 | 17.30 | 23.30 | 23.01 | |
| Return on Capital Employed (%) | 28.79 | 27.26 | 22.52 | 27.65 | 29.44 | |
| Return on Assets (%) | 18.97 | 15.91 | 12.60 | 15.54 | 17.80 | |
| Total Debt/Equity (X) | 0.00 | 0.04 | 0.14 | 0.23 | 0.00 | |
| Asset Turnover Ratio (%) | 0.93 | 0.83 | 0.78 | 0.99 | 94.75 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.29 | 2.17 | 1.87 | 1.55 | 4.32 | |
| Quick Ratio (X) | 3.21 | 2.10 | 1.82 | 1.46 | 4.16 | |
| Inventory Turnover Ratio (X) | 78.67 | 77.35 | 0.00 | 0.00 | 38.28 | |
| Dividend Payout Ratio (NP) (%) | 40.20 | 51.89 | 34.00 | 33.62 | 35.38 | |
| Dividend Payout Ratio (CP) (%) | 31.66 | 43.27 | 26.55 | 27.59 | 28.32 | |
| Earnings Retention Ratio (%) | 59.80 | 48.11 | 66.00 | 66.38 | 64.62 | |
| Cash Earnings Retention Ratio (%) | 68.34 | 56.73 | 73.45 | 72.41 | 71.68 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 19,947.40 | 18,288.37 | 14,941.29 | 21,534.52 | 21,676.61 | |
| EV/Net Operating Revenue (X) | 8.48 | 9.30 | 8.45 | 11.50 | 14.54 | |
| EV/EBITDA (X) | 25.67 | 29.53 | 29.45 | 38.23 | 47.26 | |
| MarketCap/Net Operating Revenue (X) | 8.81 | 9.60 | 8.61 | 11.60 | 15.14 | |
| Retention Ratios (%) | 59.79 | 48.10 | 65.99 | 66.37 | 64.61 | |
| Price/BV (X) | 9.71 | 9.94 | 9.02 | 14.72 | 18.54 | |
| Price/Net Operating Revenue | 8.81 | 9.60 | 8.61 | 11.60 | 15.14 | |
| Earnings Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
12.02.2026
05.02.2026
Dr Lal PathLab Consolidated December 2025 Net Sales at Rs 659.80 crore, up 10.57% Y-o-Y
03.02.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
05.02.2026
Dr Lal PathLab Consolidated December 2025 Net Sales at Rs 659.80 crore, up 10.57% Y-o-Y
03.02.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
10.11.2025
Dr Lal PathLab Standalone September 2025 Net Sales at Rs 699.60 crore, up 19.82% Y-o-Y
06.10.2021
Dr. Lal PathLabs Q2 PAT seen up 28.4% YoY to Rs 112 cr: Prabhudas Lilladher
18.01.2021
Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher
11.10.2019
Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak
15.07.2019
Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth